title: Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
abstract: OBJECTIVE
  Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. The aim of the present study was to clarify whether there is any difference in the speed of symptom relief in patients with reflux esophagitis following the administration of these three proton pump inhibitors (PPI).
  
  
  METHODS
  Eighty-five patients with erosive reflux esophagitis were randomized to receive 8 weeks of 20 mg of omeprazole (n = 30), 30 mg of lansoprazole (n = 25), or 20 mg of rabeprazole (n = 30) once a morning. Daily changes in heartburn and acid reflux symptoms in the first 7 days of administration were assessed using a six-point scale (0: none, 1: mild, 2: mild-moderate, 3: moderate, 4: moderate-severe, 5: severe).
  
  
  RESULTS
  The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI. Complete heartburn remission also occurred more rapidly in patients administered rabeprazole (compared with omeprazole: P = 0.035, compared with lansoprazole: P = 0.038 by log-rank test). No differences were seen in the rate of endoscopic healing of reflux esophagitis at 8 weeks between the three treatment regimens.
  
  
  CONCLUSIONS
  Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis.
authors.affiliation: Department of Internal Medicine II, Shimane Medical University, Department of Internal Medicine, Unnan General Hospital, Shimane, Japan. kadachi@shimane-med.ac.jp
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Adachi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Naoharu
authors.initials: N
authors.lastname: Hamamoto
authors.forename: Kazuya
authors.initials: K
authors.lastname: Hirakawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Niigaki
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyake
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Taniura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ono
authors.forename: Takekazu
authors.initials: T
authors.lastname: Kaji
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suetsugu
authors.forename: Junko
authors.initials: J
authors.lastname: Yagi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Komazawa
authors.forename: Takafumi
authors.initials: T
authors.lastname: Mihara
authors.forename: Tomoko
authors.initials: T
authors.lastname: Katsube
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Fujishiro
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Shizuku
authors.forename: Shuzo
authors.initials: S
authors.lastname: Hattori
authors.forename: Shun
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000150:complications*; D005260:Female; D006356:Heartburn / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D009853:Omeprazole